Elle DigestLifestyle, beauty and consumer releases

Health & Medical · Week of Nov 2, 2026

Q3 results and raised guidance: the week in health releases

Third quarter results dominated, with Evolent, Waters and Caris raising full-year guidance, alongside a board change, a reverse split and a DBS initiative.

· Elle Digest newsroom

Third quarter 2026 earnings made up most of the week's releases. Waters Corporation and Caris Life Sciences raised full-year revenue guidance, and Evolent Health raised its Adjusted EBITDA outlook while reiterating revenue guidance. Revenue rose year over year at Evolent, Caris and Waters, which also reported revenue from its acquired Biosciences and Diagnostic Solutions businesses and announced its acquisition of MOBILion Systems. Trulieve Cannabis reported lower revenue after deconsolidating its Harvest operations but swung to net income. Margins were a recurring point: Evolent's medical expense ratio rose to 93.0% and Caris reported lower gross margin.

Outside earnings, DarioHealth named John R. Palumbo chairman, and Accuray approved a 1-for-40 reverse stock split it says is meant to help it regain compliance with Nasdaq's minimum bid price requirement. Medtronic and The Michael J. Fox Foundation for Parkinson's Research issued parallel releases on an educational initiative about deep brain stimulation for people with Parkinson's disease.

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Elle Digest reporting.